Trial Details

Recruiting
Basic Information
Clinical ID c2467
Identifier NL-OMON25639
Trial Title Title *_Vaccinations in Immunocompromised Patients, Rabies Antibody Response after pre exposure prophylaxis - The VIPRAR study_
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Auto-immune diseases (Inflammatory bowel disease/rheumatoid arthritis)
Interventions We offer all eligible ICPs a three-dose rabies PrEP schedule on days 0, 7 and 21-28 intramuscularly, according to the current WHO guidelines for ICPs. At month 12, a 2-dose rabies PEP schedule will be administered intramuscularly at day 0 and day 3. Serum samples will be taken on day 0, day 28, day 60, month 12 and month 12+ 7 days to determine rabies antibody levels. The Rapid Focus Fluorescent Inhibition Test (RFFIT) is considered the gold standard to determine rabies antibodies. All blood samples will be sent to an external rabies reference center for RFFIT. Antibody levels above 0.5IU/L will be considered as adequate according to WHO definitions.
Participant Information
Sponsor The International Society of Travel Medicine (ISTM)
City -
Country/Region -
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement -
Study Design
Study Type Interventional
Phase Not Available
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -